{"doi":"10.1002/ehf2.14546","title":"MicroRNA-30d and -483-3p for Bi-Ventricular Remodelling and miR-126-3p for Pulmonary Hypertension in Advanced Heart Failure","abstract":"<jats:title>Abstract</jats:title>\n                  <jats:sec>\n                    <jats:title>Aims</jats:title>\n                    <jats:p>MicroRNAs play a role in pathogenic mechanisms leading to heart failure. We measured a panel of 754 miRNAs in the myocardial tissue and in the serum of patients with heart failure with reduced ejection fraction due to dilatative idiopathic cardiomyopathy (DCM, N = 10) or ischaemic cardiomyopathy (N = 3), referred to left ventricular assist device implant. We aim to identify circulating miRNAs with high tissue co-expression, significantly associated to echocardiographic and haemodynamic measures.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results</jats:title>\n                    <jats:p>We have measured a panel of 754 miRNAs in the myocardial tissue [left ventricular (LV) apex] and in the serum obtained at the same time in a well selected study population of end-stage heart failure with reduced ejection fraction due to either DCM or ischaemic cardiomyopathy, referred to continuous flow left ventricular assist device implant. We observed moderate agreement for miR-30d, miR-126-3p, and miR-483-3p. MiR-30d was correlated to LV systolic as well as diastolic volumes (r = 0.78, P = 0.001 and r = 0.80, P = 0.005, respectively), while miR-126-3p was associated to mPAP and PCWP (r = −0.79, P = 0.007 and r = −0.80, P = 0.005, respectively). Finally, serum miR-483-3p had an association with right ventricular end diastolic diameter (r = −0.73, P = 0.02) and central venous pressure (CVP) (r − 0.68 p 0.03).</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions</jats:title>\n                    <jats:p>In patients with DCM, few miRNAs are co-expressed in serum and tissue: They are related to LV remodelling (miR-30d), post-capillary pulmonary artery pressure (miR-126-3p), and right ventricular remodelling/filling pressures (miR-483-3p). Further studies are needed to confirm their role in diagnosis, prognosis or as therapeutic targets in heart failure with reduced ejection fraction.</jats:p>\n                  </jats:sec>","journal":"ESC Heart Failure","year":2024,"id":616844,"datarank":0.4515526434209353,"base_score":2.3978952727983707,"endowment":2.3978952727983707,"self_citation_contribution":0.3596842909197557,"citation_network_contribution":0.09186835250117964,"self_endowment_contribution":0.3596842909197557,"citer_contribution":0.09186835250117964,"corpus_percentile":null,"corpus_rank":null,"citation_count":10,"citer_count":9,"citers_with_citation_signal":7,"citers_with_endowment":7,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":324363,"name":"Valentina Agnese","orcid":"0000-0002-0548-0926","position":1,"is_corresponding":false},{"id":1590495,"name":"Sergio Sciacca","orcid":null,"position":2,"is_corresponding":false},{"id":1590496,"name":"Cesare Scardulla","orcid":null,"position":3,"is_corresponding":false},{"id":424390,"name":"Manlio Cipriani","orcid":"0000-0002-0632-0561","position":4,"is_corresponding":false},{"id":324365,"name":"Michele Pilato","orcid":"0000-0003-0390-0664","position":5,"is_corresponding":false},{"id":19408,"name":"Jae K. Oh","orcid":"0000-0002-8303-5780","position":6,"is_corresponding":false},{"id":324368,"name":"Salvatore Pasta","orcid":"0000-0002-4841-2560","position":7,"is_corresponding":false},{"id":1590497,"name":"Joseph Maalouf","orcid":null,"position":8,"is_corresponding":false},{"id":1590498,"name":"Pier Giulio Conaldi","orcid":null,"position":9,"is_corresponding":false},{"id":1590499,"name":"Diego Bellavia","orcid":null,"position":10,"is_corresponding":false},{"id":1590494,"name":"Alessia Gallo","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"MicroRNA-30d and -483-3p for Bi-Ventricular Remodelling and miR-126-3p for Pulmonary Hypertension in Advanced Heart Failure","abstract":"<jats:title>Abstract</jats:title>\n                  <jats:sec>\n                    <jats:title>Aims</jats:title>\n                    <jats:p>MicroRNAs play a role in pathogenic mechanisms leading to heart failure. We measured a panel of 754 miRNAs in the myocardial tissue and in the serum of patients with heart failure with reduced ejection fraction due to dilatative idiopathic cardiomyopathy (DCM, N = 10) or ischaemic cardiomyopathy (N = 3), referred to left ventricular assist device implant. We aim to identify circulating miRNAs with high tissue co-expression, significantly associated to echocardiographic and haemodynamic measures.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results</jats:title>\n                    <jats:p>We have measured a panel of 754 miRNAs in the myocardial tissue [left ventricular (LV) apex] and in the serum obtained at the same time in a well selected study population of end-stage heart failure with reduced ejection fraction due to either DCM or ischaemic cardiomyopathy, referred to continuous flow left ventricular assist device implant. We observed moderate agreement for miR-30d, miR-126-3p, and miR-483-3p. MiR-30d was correlated to LV systolic as well as diastolic volumes (r = 0.78, P = 0.001 and r = 0.80, P = 0.005, respectively), while miR-126-3p was associated to mPAP and PCWP (r = −0.79, P = 0.007 and r = −0.80, P = 0.005, respectively). Finally, serum miR-483-3p had an association with right ventricular end diastolic diameter (r = −0.73, P = 0.02) and central venous pressure (CVP) (r − 0.68 p 0.03).</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions</jats:title>\n                    <jats:p>In patients with DCM, few miRNAs are co-expressed in serum and tissue: They are related to LV remodelling (miR-30d), post-capillary pulmonary artery pressure (miR-126-3p), and right ventricular remodelling/filling pressures (miR-483-3p). Further studies are needed to confirm their role in diagnosis, prognosis or as therapeutic targets in heart failure with reduced ejection fraction.</jats:p>\n                  </jats:sec>","is_dataset_classified":null,"base_score":2.3978952727983707,"endowment":2.3978952727983707,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"37864482","pmcid":"PMC10804158","openalex_id":"https://openalex.org/W4387845732","authors":[],"funders":[{"funder_name":"Ministero della Salute","grant_id":"2774461","title":null}],"total_grants":1,"fwci":0.802,"citation_percentile":0.66393983,"influential_citations":0,"citation_trend":[{"year":2023,"count":1},{"year":2024,"count":2},{"year":2025,"count":3},{"year":2026,"count":4}],"oa_status":"gold","license":"cc-by-nc-nd","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ehf2.14546","host_type":"journal"},{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ehf2.14546","host_type":"publisher"},{"url":"https://academic.oup.com/eschf/article-pdf/11/1/155/64509020/eschf_11_1_155.pdf","host_type":"publisher"},{"url":"https://doi.org/10.1002/ehf2.14546","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/37864482","host_type":"repository"},{"url":"https://hdl.handle.net/10447/618015","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10804158","host_type":"repository"},{"url":"https://doaj.org/article/824fa83235a44b668300e561d018f8c5","host_type":"repository"},{"url":"https://iris.unipa.it/bitstream/10447/618015/2/Gallo_2023_ESCHeartFailure_MicroRNA%e2%80%9030d%20and%20%e2%80%90483%e2%80%903p%20for%20bi%e2%80%90ventricular%20remodelling%20and%20miR%e2%80%90126%e2%80%903p%20for%20pulmonary.pdf","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10804158/pdf/EHF2-11-155.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC10804158","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC10804158?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Mechanical Circulatory Support Devices","Cardiac Structural Anomalies and Repair","Cardiovascular Function and Risk Factors"],"mesh_terms":["Heart Failure","Humans","Hypertension, Pulmonary","Cardiomyopathies","Myocardial Ischemia","Ventricular Dysfunction, Left","Ventricular Remodeling","MicroRNAs"],"keywords":["Medicine","Cardiology","Internal medicine","Ejection fraction","Heart failure","Dilated cardiomyopathy","Ischemic cardiomyopathy","Pulmonary artery","Diastole","Cardiomyopathy","Hemodynamics","Central venous pressure","Vascular resistance","Blood pressure","Heart rate","Diagnosis","Prognosis","Biomarkers","microRNAs"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-03T00:04:06.741122Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}